Fig. 4: Regorafenib induces a tumor-promoting micromilieu by enhancing the infiltration of M2-macrophages. | British Journal of Cancer

Fig. 4: Regorafenib induces a tumor-promoting micromilieu by enhancing the infiltration of M2-macrophages.

From: Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis

Fig. 4: Regorafenib induces a tumor-promoting micromilieu by enhancing the infiltration of M2-macrophages.The alternative text for this image may have been generated using AI.

Murine bone marrow macrophages from non-transgenic mice were polarized into M1 and M2 macrophages (or left untreated) and were treated with 0.5 µM Regorafenib for 24 h. a Effect on cell viability was assessed by an ATP-based CellTiter Glo Assay. Values are shown relative to DMSO-control. b Western blot analysis showing PARP-1 (n = 3) as well as total (n = 3) and phosphorylated amount of CSF1R (Tyr723) (n = 2) (fl: full-length PARP-1; cl: cleaved PARP-1 fragment at 89 kDa). β-actin was used as a loading control. All protein lysates were run on one single gel, but additional treatment conditions that were originally loaded on the gel were cut out. c + g Percentage of F4/80-positive cells in the tumor, d + h representative F4/80-staining and (e + i) percentage of CSF1R-positive cells in the tumor of Regorafenib- and PEG-treated mice during tumor development (PEG: n = 6; Rego: n = 8) and tumor progression (PEG: n = 7; Rego: n = 10) with representative CSF1R-staining (f + j). Boxplot data are presented as mean ± SD by Mann–Whitney U test. *p ≤ 0.05; ns=non-significant.

Back to article page